Innate Pharma and IFLI Announce Up to $7.9M Investment for IPH6501 Development in Follicular Lymphoma

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into a strategic partnership to investigate the potential of IPH6501, Innate’s anti-CD20 ANKET® (Antibody-based NK cell Engager Therapeutics), in the treatment of…









